Effect of Lixisenatide in Type 1 Diabetes (LIXI) Study

Chief investigator:Stephen Gough

Sponsor:University of Oxford

Funder:Sanofi Aventis Groupe

Reference numbers:ISRCTN00290196
EudraCT 2013-002259-14

The LIXI study aimed to determine whether administration of lixisenatide, a Glucagon Like Peptide-1 receptor agonist could improve glycaemic control when added to insulin therapy in people with type 1 diabetes.

Design

Open-label, non-randomised dose-finding pilot stud, followed by a randomised, placebo-controlled, double-blind, cross over trial.

Results

Lixisenatide suppressed glucagon and reduced postprandial glycaemia without compromising counter-regulatory responses during induced hypoglycaemia. The results are currently being submitted for publication.